JP2016520636A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520636A5
JP2016520636A5 JP2016517274A JP2016517274A JP2016520636A5 JP 2016520636 A5 JP2016520636 A5 JP 2016520636A5 JP 2016517274 A JP2016517274 A JP 2016517274A JP 2016517274 A JP2016517274 A JP 2016517274A JP 2016520636 A5 JP2016520636 A5 JP 2016520636A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
phenyl
acceptable salt
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016517274A
Other languages
English (en)
Japanese (ja)
Other versions
JP6396438B2 (ja
JP2016520636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/061501 external-priority patent/WO2014195322A1/en
Publication of JP2016520636A publication Critical patent/JP2016520636A/ja
Publication of JP2016520636A5 publication Critical patent/JP2016520636A5/ja
Application granted granted Critical
Publication of JP6396438B2 publication Critical patent/JP6396438B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016517274A 2013-06-04 2014-06-03 トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 Expired - Fee Related JP6396438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350684 2013-06-04
SE1350684-5 2013-06-04
PCT/EP2014/061501 WO2014195322A1 (en) 2013-06-04 2014-06-03 Triazole compounds and their use as gamma secretase modulators

Publications (3)

Publication Number Publication Date
JP2016520636A JP2016520636A (ja) 2016-07-14
JP2016520636A5 true JP2016520636A5 (enExample) 2017-06-01
JP6396438B2 JP6396438B2 (ja) 2018-09-26

Family

ID=50896282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517274A Expired - Fee Related JP6396438B2 (ja) 2013-06-04 2014-06-03 トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用

Country Status (7)

Country Link
US (1) US9718805B2 (enExample)
EP (1) EP3004080B1 (enExample)
JP (1) JP6396438B2 (enExample)
CN (1) CN105263922B (enExample)
DK (1) DK3004080T3 (enExample)
ES (1) ES2701810T3 (enExample)
WO (1) WO2014195322A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060353T2 (hu) * 2015-02-25 2023-02-28 Prilenia Neurotherapeutics Ltd Pridopidin alkalmazása memória javítására
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP2019537582A (ja) * 2016-10-31 2019-12-26 ハフ イアー インスティテュート シナプス形成および神経突起形成を増強するための方法
CN121202886A (zh) * 2024-06-26 2025-12-26 浙江养生堂天然药物研究所有限公司 杂环类化合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030312A1 (it) 2003-02-21 2004-08-22 Chiesi Farma Spa Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer.
CA2534240A1 (en) 2003-08-07 2005-02-17 Merck Sharp & Dohme Limited Treatment for alzheimer's disease and related conditions
JP2007513128A (ja) 2003-12-03 2007-05-24 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病および関連状態の治療に有用な１−アルキル−３−チオ置換インドール−２−アルキン酸
CN101723900B (zh) 2004-05-26 2012-08-22 卫材R&D管理有限公司 肉桂酰胺类化合物
US8389547B2 (en) 2006-04-26 2013-03-05 Yudith Garcia Piperidines and related compounds for the treatment of Alzheimer's disease
JPWO2007135969A1 (ja) 2006-05-19 2009-10-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア系−シンナミド誘導体
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2120573A4 (en) 2007-02-12 2011-05-25 Merck Sharp & Dohme piperidine
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
CA2695543A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
CA2698341A1 (en) * 2007-09-06 2009-03-12 Schering Corporation Gamma secretase modulators
WO2009087127A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta
JP5328816B2 (ja) 2008-02-22 2013-10-30 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβの調節薬
CN102272133A (zh) 2008-11-06 2011-12-07 阿斯利康(瑞典)有限公司 淀粉样β的调节剂
WO2010052199A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
UY32622A (es) 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
KR20120050450A (ko) * 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
EP2523955B1 (en) * 2010-01-15 2014-07-16 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production

Similar Documents

Publication Publication Date Title
JP2016520635A5 (enExample)
RU2017114355A (ru) Производные нафтиридина в качестве антагонистов альфа v бета 6 интегрина для лечения, в частности, фиброзных заболеваний
JP2012508734A5 (enExample)
JP2016516043A5 (enExample)
JP2014513110A5 (enExample)
JP2017528504A5 (enExample)
JP2009542716A5 (enExample)
JO3754B1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
JP2017528503A5 (enExample)
JP2016538313A5 (enExample)
JP2017528506A5 (enExample)
HRP20120969T1 (hr) Spoj azola
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
JP2016522835A5 (enExample)
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
SI3050882T1 (en) Piperidin-4-yl azetidine derivatives, as inhibitors of JAK1
ME01462B (me) Vinilindazolilna jedinjenja"
JP2016520636A5 (enExample)
JP2018534286A5 (enExample)
JP2016513696A5 (enExample)
PE20160550A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
JP2015522592A5 (enExample)
JP2015500223A5 (enExample)
AR068921A1 (es) Derivados heterociclicos de tetrazol y 1,2-4 triazoles, composiciones farmaceuticas que los contienen y usos de los mismos para tratar desordenes neurologicos, gastrointestinales y del dolor,entre otros.
JP2013506674A5 (enExample)